Evid Based Nurs 7:50 doi:10.1136/ebn.7.2.50
  • Treatment

Review: regular inhaled short acting β2 agonists improve lung function in stable chronic obstructive pulmonary disease

Regular inhaled short acting β2 agonists for ⩾7 days v placebo for stable chronic obstructive pulmonary disease*

Outcomes at 1–8 weeks Number of trials (n) Weighted mean difference (95% CI)
*FEV1  =  forced expiratory volume in 1 second; FVC  =  forced vital capacity; PEFR  =  peak expiratory flow rate. Other abbreviations defined in glossary.
†Post-bronchodilator; positive numbers favour β2 agonists.
‡Treatment failure  =  number of dropouts because of worsening symptoms.
§Information provided by author.
| |Calculated from relative risk and control event rate in article.
FEV1 (l)† 6 (196) 0.14 (0.04 to 0.25)
FVC (l)† 4 (116) 0.30 (0.02 to 0.58)
Morning PEFR (l/min)† {4 (124)}§ 29.17 (0.25 to 58.09)
Evening PEFR (l/min)† {3 (86)}§ 36.75 (2.56 to 70.94)
Standardised mean difference (CI)
Breathlessness (100 mm visual analogue score) 4 {94}§ 1.33 (1.01 to 1.65)
Treatment failure‡ 5 (198) 51% (27 to 67)| | {5 (3 to 9)}§
Patient preference for β2 agonists over placebo 4 (158) {507% (198 to 1135)}§ {3 (2 to 3)}§

This Article

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article